Getting to know Chathuri Daluwatte, an Alexion R&D Leading Voice
Artificial Intelligence (AI) is rapidly advancing and has the potential to have a transformative impact on clinical research and development (R&D). We spoke to Chathuri Daluwatte, who leads Alexion’s AI Diagnostics team, about the opportunity for AI technology to shorten the diagnostic journey for rare disease patients and her personal connection that drives her work.
Can you explain the role of the AI Diagnostics team?
First, I think it is helpful to define how we think about AI, which can have a multitude of definitions across industries. In the life sciences industry, we consider it a calculation or an algorithm that goes beyond rule-based calculation to reach a solution. The AI diagnostic team at Alexion is focused on exploring and harnessing opportunities to use these algorithms to improve the diagnostic journey for rare disease patients.
This is critical because the diagnostic experience, which is often referred to as a diagnostic odyssey, can be long and arduous, especially when a patient’s disease is not well understood. This is far too common for people living with rare diseases, where it can take an average of five years, but often longer, and involve visits to an average of seven specialists to reach an accurate diagnosis. We believe that AI can have a significant impact on this journey, enabling patients to get answers more quickly.
How do you see AI helping to shorten the diagnostic odyssey?
I am in an interesting position as both a patient and an expert in the field. I live with a rare disease that took 12 years to accurately diagnose, and I can attest to the acute challenges associated with getting answers when physician awareness of your condition is low. My own experience is a prime example of the opportunity AI represents.
The first test to try to identify the cause of my symptoms was an ultrasound, evaluated by someone who was not a rare disease specialist, and I didn’t receive a diagnosis from that test. Twelve years later, I was diagnosed after an ultrasound test was reviewed by a rare disease specialist. I believe that if that first health care professional had been able to use AI on my original ultrasound, it would have prompted them to consider my rare disease, even though they weren't an expert on the subject.
The idea is that AI will enable knowledge, normally concentrated among experts and specialists, to be widely accessible across patient care teams, especially among frontline healthcare providers—where rare disease patients typically begin their diagnostic journey. These technologies have the potential to help physicians parse through a wealth of data and identify patterns that could help them to more rapidly reach an accurate diagnosis.
How did you get involved in this field?
My interest started with computer programming as a child. I wrote my first program when I was 10 years old, and since then, I’ve always had a passion for computer science. I liked the experience of creating something that didn’t exist, and AI is powering a lot of those opportunities today. I have always been curious about biology as well so I sought a path that would allow me to merge these two disciplines.
I got my PhD in Biomedical Engineering and have since dedicated my career to harnessing the power of AI to support the life sciences. I started with roles in medical devices and that ultimately led me to work in the pharmaceutical industry where there is immense potential to bridge medicine and technology through AI to improve outcomes for patients.
What about your work excites you the most?
I am very optimistic about what I view as the unlimited potential of AI across a spectrum of diagnostics. A growing investment is being made across the healthcare industry in this technology, and we’re primed as an organization to innovate with this technology to improve the patient experience.
In addition to AI’s role in fostering greater awareness of rare diseases, there’s a wealth of opportunity to harness AI to support clinical development, including trial enrolment, companion diagnostics and digital therapeutics. I thrive on exploring new areas of study, and there is so much uncharted territory in AI.
Alexion as a leader in rare disease is really invested in advancing these possibilities. The collaborative nature of this organization and our culture of rolling up our sleeves to get the work done for the people who need it most positions us to deliver on this potential, and that is really thrilling.
What’s one lesson you’ve learned from working in rare disease R&D?
I’ve learned the importance of diversity of thinking, which is critical for the development and advancement of AI as well as many other aspects of rare disease R&D. By this I mean concepts like gender or race, but also the practice of medicine. When it comes to AI’s utility, it is only as valuable as the data we give it. It’s imperative that we continue to champion bringing all angles of diversity into every aspect of our work, so the data AI is using is reflective of the people we seek to help. Only then can we fully leverage the potential of AI to drive meaningful change and ensure no one is left behind as this technology — and the diagnostic advances it enables — evolves.
Learn more about our scientists, innovative culture and career opportunities at Alexion.
More articles you may like
Article • June 08, 2026
From Unseen to Seen: Why Making Rare Diseases Visible Matters for Access to Care in the United States
Across the United States, more than 30 million people are living with a rare disease.1 Yet for too many patients and their families, these conditions remain unrecognized within healthcare systems. On average, an accurate diagnosis can take five years or more, though access to care varies by geography, and the full physical, social and economic impact of rare diseases is obscured by fragmented data systems.
Article • May 18, 2026
Caring for the Caregivers: Mental Health in Rare Disease
Across the United States, millions of families are navigating the complexities of rare disease. Behind many of these journeys is a caregiver coordinating appointments, advocating for access and care, balancing responsibilities at home and work, and carrying a significant emotional load.
Recognizing the toll these challenges can have on families, Alexion, AstraZeneca Rare Disease collaborated with caregivers and mental health professionals to develop More Than Rare, a three-part webinar series focused on patient and caregiver mental health.
Article • May 11, 2026
Tina’s Big Trip: A rare disease story about going the extra mile
Tina’s Big Trip: A rare disease story about going the extra mile, is the newest title in Alexion, AstraZeneca Rare Disease’s Inspired By book series created to support the rare disease community, and especially families impacted by rare diseases. The story, which follows two sisters preparing for a journey to Italy with their father, reflects the daily resilience that families demonstrate while managing the unseen complexities of living with a rare disease.
Article • February 03, 2026
Advancing Policy, Partnerships and Progress for the Rare Disease Community
As we reflect ahead of Rare Disease Day, we reaffirm our commitment to pioneering innovations for the rare disease community and to shortening the time to diagnosis, improving access to lifesaving care, and advancing health care policies that support patients and families.
Clinical Trials • October 28, 2025
Shaping the future of R&D with real world insights into rare disease
Studying a rare disease often involves working with fragmented information, much like piecing together scattered pages of different books, each offering part of the story but rarely forming a complete picture. Researchers face this challenge due to small, often underdiagnosed, patient populations and limited understanding of how these diseases progress over time.
Diagnostics • September 17, 2025
Genomic Innovation to Support Newborn Screening of Rare Diseases
Today, while more than 10,000 rare diseases are known, recommended newborn screening panels cover only about 40 core conditions. This gap underscores the need for innovative approaches to expand the reach of newborn screening.
Thought Leadership • June 11, 2025
Paving Regulatory Pathways in Rare Disease
Many rare disease medicines are often a first of their kind, and a clear roadmap for their development and approval does not exist. Navigating the complex and sometimes unprecedented regulatory environment for rare disease requires innovation, collaboration and a patient-first mindset.
Media [News] • April 10, 2025
Advancing Rare Disease Research Through Patient-Centric Trial Design
As Head of Development, Regulatory and Safety at Alexion, Gianluca Pirozzi channels his life’s experience with rare disease to inform his work at Alexion, ensuring clinical programmes are fueled by a patient-focused mindset.
Article • February 24, 2025
Supporting Patients on Rare Disease Day, and Every Day
Rare Disease Day recognizes the 400 million people worldwide – and 30 million in the United States – who are living with a rare disease. While significant progress has been made in understanding rare diseases and developing treatments, the need for continued awareness, research and support is as great as ever.
Patient Support • February 05, 2025
Addressing the Unmet Needs of the Amyloidosis Community
We spoke with Cristina Quarta, Executive Medical Director, about a group of rare diseases known as amyloidosis, the medical needs within this community and how her work as a cardiologist shapes her approach to research and development (R&D) for rare cardiac conditions.